SURFACING NEW INSIGHTS, TOGETHER MOBILE APP FOR THOSE LIVING WITH DIABETES Collaboration between IBM Watson Health and Medtronic
Medtronic and IBM Watson Health: Surfacing New Insights Together
Watch how IBM Watson Health and Medtronic collaborated on the development of Sugar. IQ, a first-of-its-kind mobile app for those living with diabetes.
More information (see more)Less information (see less)
Dr. Lisa Latts doesn’t mince words.
“In healthcare, we have a data problem,” she says. “There’s too much of it for humans to handle.”
Dr. Latts is Chief Deputy Health Officer at IBM Watson Health, a company leveraging the power of artificial intelligence, natural language processing, deep learning, analytics, and other tools to make sense of complex data. All this with the hope it will make a difference for patients.
In 2015, shortly after opening its doors as a healthcare company, IBM Watson Health set its sights on trying to improve the lives of people living with diabetes. Could the team there provide key analytics to help people manage their blood sugar levels? Help predict potentially critical issues? Empower patients to play an active role in their own care and spend less time in the hospital?
“If we can get someone engaged, help them stay in a healthy blood sugar range, and prevent complications, that would move the needle in terms of the overall cost of treating diabetes,” says Dr. Latts. “And ultimately, it improves the quality of life for the individual.”
Leaders at IBM Watson Health knew it would take more than data scientists. It’s why they teamed up with Medtronic, a leader in diabetes management technology with a keen eye on the patient perspective.
“It was absolutely critical,” said Dr. Latts. “There was no way we could have done it without a strong partner like Medtronic.”
The two companies share a common vision — to improve outcomes and reduce costs in healthcare. And both knew their strengths and where they’d need help.
“Being a strong partner requires humility,” says Laura Stoltenberg, Vice President of Multiple Daily Injections (MDI) Solutions at Medtronic Diabetes. “It means recognizing that all the industry knowledge doesn’t reside in the four walls of Medtronic.”
Outside of a few doctor visits each year, people living with diabetes are tasked with managing more than 95 percent of their care. This includes healthy eating, exercising, monitoring blood sugar, taking medication, reducing risk, and taking care of unexpected issues that arise. It is estimated patients are making hundreds of decisions each day related to their diabetes.
“Living with diabetes requires a ton of mental math,” says Stoltenberg. “It’s important to provide tools to help people manage their disease.” What resulted was the 2018 release of a first-of-its-kind mobile app for those living with diabetes. It leverages the power of Watson’s artificial intelligence along with Medtronic’s deep diabetes knowledge and management devices.
Called Sugar.IQ™, the “personal diabetes assistant” continually analyzes how an individual’s glucose level responds to food intake, insulin dosages, daily routines, and other information provided by the app user.
With the Sugar.IQ™ app, people with diabetes can uncover patterns and insights that affect their glucose levels, which can give them information throughout the day to help stay on track. The digital platform syncs with the Guardian Connect™ system from Medtronic — a smart continuous glucose monitoring system that provides advance warning of sugar highs and lows.
Early results show that the Sugar.IQ™ app is doing what it’s meant to do. Research presented at the American Diabetes Association 2018 conference found that people who used the Sugar.IQ app spent an average of 36 minutes more per day in healthy glucose range [70-180 mg/dL] than they did before using the app.1 The time equates to an additional nine days a year in healthy glucose range, which can provide a host of benefits.
“If we can help someone stay in range longer, that can help prevent some of the complications associated with diabetes,” says Dr. Latts. Complications often mean additional trips to the hospital or treating even more serious conditions like heart or kidney disease. And treating these conditions is costly.
“We know that one in four dollars in the healthcare system is spent on individuals with diabetes,2” says Latts. “If we can get people engaged, it could really move the needle in terms of the cost of diabetes within the healthcare system.”
Stoltenberg agrees. “Sometimes to solve the big problems in healthcare, you have to solve the day-to-day problems. And this platform is focused on that.”
Both IBM and Medtronic admit, it wasn’t an easy path to get here. “We had ups and down,” said Stoltenberg. “Sometimes it required taking a step back and looking at things from others’ points of view.” “There were stops and starts,” said Dr. Latts. “But you need open communication and a willingness to try and fail.”
While in the development phase, for example, an early version of the Sugar.IQ™ app was serving up critical insights, but the language used was too clinical. Medtronic took the time to rewrite the language into easier to understand, patient-friendly wording.
“We spend an enormous amount of time understanding patients’ needs, unique problems, wishes and aspirations so we can incorporate them into our technologies,” says Stoltenberg.
Ultimately, creating the Sugar.IQ™ app required keeping their focus on one thing: the patient.
“Anytime you can keep patients engaged in their own care, that’s when you start seeing better outcomes,” says Dr. Latts. “There are millions of people living with this disease, and we’re committed to working on their behalf.”
And working for patients today — and in the future — is ultimately what brought these two companies together.
“We’re going to see incredible things in the months and years to come,” says Dr. Latts. “We haven’t even scratched the surface of what’s possible.”
Important Safety Information: Guardian™ Connect CGM System
The Guardian Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at https://www.medtronicdiabetes.com/download-library and https://www.medtronicdiabetes.com/important-safety-information.
Oral Presentation at the 78th Annual American Diabetes Association (ADA) Scientific Sessions. Analysis based on real-world data from 256 randomly offered MiniMed 530G users from April to August 2017.